G&E Herbal Biotechnology , Ltd. Profit Margin

The latest profit margin for 4911.TWO is 40.0% as of June 2026. That compares with 45.74% in the prior-year period — down 12.6% year over year. That is above the Healthcare sector average of 9.71%. Investors often review this figure alongside G&E Herbal Biotechnology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 4911.TWO's profit margin moved from 45.74% to 40.0% — a 12.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in G&E Herbal Biotechnology , Ltd.'s valuation or profitability profile.

Against Healthcare companies, 4911.TWO currently prints 40.0% for profit margin, while the sector average sits near 9.71%. That is roughly 312.1% above the sector mean. Large gaps often invite a closer look at G&E Herbal Biotechnology , Ltd.'s growth, margins, and balance sheet.

Profit Margin shows how effectively G&E Herbal Biotechnology , Ltd. converts resources into returns. At 40.0%, 4911.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 45.74% in the prior-year period — down 12.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 4911.TWO's profit margin (40.0%), review year-over-year change from 45.74%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.